Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Vivjoa Generic Name & Formulations
Legal Class
Rx
General Description
Oteseconazole 150mg; hard gel caps.
Pharmacological Class
Azole antifungal.
How Supplied
Caps—18
Manufacturer
Generic Availability
NO
Vivjoa Indications
Indications
To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential.
Vivjoa Dosage and Administration
Adult
Swallow whole. Take with food. Vivjoa-only regimen: give 600mg (as a single dose) on Day 1; then 450mg (as a single dose) on Day 2; and then 150mg once weekly (every 7 days) starting on Day 14 for 11 weeks (Weeks 2 through 12). Fluconazole/Vivjoa regimen (prescribe fluconazole separately): give oral fluconazole 150mg once on Days 1, 4, and 7; then Vivjoa 150mg once daily for 7 days on Days 14 through 20; and then Vivjoa 150mg once weekly starting on Day 28 for 11 weeks (Weeks 4 through 14).
Children
Pre-menarchal: not established.
Vivjoa Contraindications
Contraindications
Females of reproductive potential. Pregnant and lactating women.
Vivjoa Boxed Warnings
Not Applicable
Vivjoa Warnings/Precautions
Warnings/Precautions
Embryo-fetal toxicity. Severe renal impairment (eGFR 15–29mL/min), end-stage renal disease (eGFR <15mL/min), moderate or severe hepatic impairment: not recommended.
Vivjoa Pharmacokinetics
See Literature
Vivjoa Interactions
Interactions
May potentiate BCRP substrates (eg, rosuvastatin); use lowest possible starting dose or consider reducing dose of substrate; monitor for adverse reactions.
Vivjoa Adverse Reactions
Adverse Reactions
Headache, nausea.
Vivjoa Clinical Trials
See Literature
Vivjoa Note
Not Applicable
Vivjoa Patient Counseling
See Literature
Images
